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Hypertension contributes significantly to heart failure, thus being a prominent cause of morbidity and mortality 
worldwide.1 Despite its prevalence, viable treatments for hyper-
tensive heart failure remain limited. Initially, the heart adapts 
to the increased workload resulting from hypertension to main-
tain cardiac output.2 This is achieved in part by hypertrophy of 
terminally differentiated contractile cardiomyocytes, with as-
sociated increases in size and myofibrillar content, along with 
adaptation of the myofibrillar apparatus. This process is unsus-
tainable in the long term, resulting in heart failure. Pathological 
changes include increased cardiomyocyte cell death,3 capillary 
rarefaction,4 myocardial inflammation, and increased fibrosis.5 
Developing strategies to control each of these is necessary for 
management of hypertensive heart failure,6 but reducing fi-
brosis is likely to be particularly important in reducing work-
load on cardiomyocytes and increasing myocyte survival, 
facilitating angiogenesis, and reducing inflammation.
The p38 (p38-MAPK [mitogen-activated protein kinases]) 
and JNK (c-Jun N-terminal kinases) cascades are key modula-
tors of the cell survival versus apoptosis/death balance. Both are 
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Abstract —Systemic hypertension increases cardiac workload causing cardiomyocyte hypertrophy and increased cardiac 
fibrosis. An underlying feature is increased production of reactive oxygen species. Redox-sensitive ASK1 (apoptosis signal-
regulating kinase 1) activates stress-regulated protein kinases (p38-MAPK [mitogen-activated protein kinases] and JNKs 
[c-Jun N-terminal kinases]) and promotes fibrosis in various tissues. Here, we determined the specificity of ASK1 signaling 
in the heart, with the hypothesis that ASK1 inhibitors may be used to manage fibrosis in hypertensive heart disease. Using 
immunoblotting, we established that moderate levels of H2O2 activate ASK1 in neonatal rat cardiomyocytes and perfused rat 
hearts. ASK1 was activated during ischemia in adult rat hearts, but not on reperfusion, consistent with activation by moderate 
(not high) reactive oxygen species levels. In contrast, IL (interleukin)-1β activated an alternative kinase, TAK1 (transforming 
growth factor–activated kinase 1). ASK1 was not activated by IL1β in cardiomyocytes and activation in perfused hearts was 
due to increased reactive oxygen species. Selonsertib (ASK1 inhibitor) prevented activation of p38-MAPKs (but not JNKs) 
by oxidative stresses in cultured cardiomyocytes and perfused hearts. In vivo (C57Bl/6J mice with osmotic minipumps for 
drug delivery), selonsertib (4 mg/[kg·d]) alone did not affect cardiac function/dimensions (assessed by echocardiography). 
However, it suppressed hypertension-induced cardiac hypertrophy resulting from angiotensin II (0.8 mg/[kg·d], 7d), with 
inhibition of Nppa/Nppb mRNA upregulation, reduced cardiomyocyte hypertrophy and, notably, significant reductions in 
interstitial and perivascular fibrosis. Our data identify a specific reactive oxygen species→ASK1→p38-MAPK pathway in 
the heart and establish that ASK1 inhibitors protect the heart from hypertension-induced cardiac remodeling. Thus, targeting 
the ASK1→p38-MAPK nexus has potential therapeutic viability as a treatment for hypertensive heart disease.  
Graphic Abstract—A graphic abstract is available for this article. (Hypertension. 2020;76:1208-1218. DOI: 10.1161/
HYPERTENSIONAHA.119.14556.) • Data Supplement
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implicated in the development of heart failure,7 being activated 
in cardiomyocytes and the heart by pathophysiological stresses 
such as redox stress and proinflammatory cytokines, including 
IL (interleukin)-1β.8 p38-MAPKs and JNKs are generally acti-
vated in parallel, the only well-documented exception being with 
ischemia where there is selective activation of p38-MAPKs.9 
Hypertension is associated with increased redox stress and 
some degree of inflammation,10 so modulating p38-MAPK or 
JNK activities may be therapeutically beneficial in hypertensive 
heart failure. p38-MAPKs and JNKs are, of themselves, poten-
tial therapeutic targets but, because of their role in inflamma-
tion,11 it may be more desirable to target specific inputs into the 
cascade to modulate activity rather than block the signal com-
pletely. p38-MAPKs and JNKs are phosphorylated/activated 
by upstream MKKs (MAPK kinases), MKK3/6, and MKK4/7, 
respectively. These are phosphorylated/activated by upstream 
MAP3Ks (MKK kinases) which are more numerous, potentially 
responding selectively to specific stresses.12 The greater diver-
sity at the MAP3K level provides increased potential for selec-
tive targeting. Two such kinases are MAP3K5 (ASK1 [apoptosis 
signal-regulating kinase 1]) and MAP3K7 (TAK1 [transform-
ing growth factor–activated kinase 1]), each of which has been 
placed upstream of both p38-MAPKs and JNKs in noncardiac 
cells where they regulate cell death responses.13
ASK1 is activated by myriad cues that alter the cellular 
redox balance.14,15 ASK1 is inhibited by association with thio-
redoxin, oxidation of which (by elevated ROS [reactive ox-
ygen species], such as H2O2) induces complex dissociation 
and ASK1 autophosphorylation of the activation loop (Thr838 
in humans; Thr845 in mice/rats). ASK1 is associated with de-
velopment of fibrosis in various tissues and is a therapeutic 
target for fibrotic diseases, including pulmonary arterial hy-
pertension, chronic kidney disease, and nonalcoholic steato-
hepatitis. Indeed, ASK1 inhibitors have been developed and 
passed into phase-III clinical trials.16,17 In the heart, ASK1 is 
activated in mouse models of pressure-overload,14 ischemia/
reperfusion,18 myocardial infarction,14 and hypertension in-
duced by Ang II (angiotensin II),19 all of which are associated 
with increased ROS. Furthermore, studies in global ASK1 
knockout mice demonstrate reduced cardiac cell death and 
remodeling in models of myocardial infarction,20 indicating 
that it plays a detrimental role. How ASK1 might be involved 
in cardiac hypertrophy and remodeling is still far from clear. 
Nevertheless, therapies targeting ASK1 are in development,21 
and cardiac ASK1 is an attractive target for heart failure.22
Here, we addressed the hypothesis that (since hyperten-
sion is associated with hypoxia and ROS) ASK1 is likely to 
be a prominent cardiac MAP3K in hypertension, and (because 
ASK1 promotes fibrosis in other tissues) its inhibition po-
tentially reduces cardiac fibrosis. With reports that ASK1 is 
activated by various stimuli and signals nonselectively to p38-
MAPKs and JNKs, we first clarified and delineated the ASK1 
signaling pathway in the heart, establishing that ASK1 was 
specifically and selectively activated by moderate levels of 
redox stress, signaling selectively to p38-MAPK (not JNKs). 
ASK1, therefore, has an appropriate profile for cardiac acti-
vation in hypertension where, given its profibrotic effects in 
other tissues, it may promote cardiac fibrosis. Consistent with 
this, selonsertib (GS-4997), an ASK1 inhibitor developed 
as an antifibrotic agent for nonalcoholic steatohepatitis,16 
reduced cardiac fibrosis, and remodeling in mice treated with 
Ang II. Thus, ASK1 inhibitors represent a viable therapeutic 
modality for fibrosis in hypertensive heart disease.
Methodology
See the Data Supplement for a full description of materials and meth-
ods. Descriptions of cell/animal experiments are provided below. 
Data from this study are available from the corresponding authors 
upon reasonable request.
Neonatal rat ventricular myocytes were prepared and adult rat 
hearts perfused as described previously.8,23,24 Cells were exposed 
to H2O2 or IL1β at the concentrations/times indicated. In some ex-
periments, cells were preincubated with selonsertib before treatment 
with H2O2 or IL-1β. Hearts were equilibrated (15 minutes) and then 
perfused with H2O2 or IL1β, or subjected to global ischemia with/
without reperfusion. In some experiments, hearts were perfused with/
without selonsertib or N-acetyl cysteine during the equilibration 
phase. Control hearts were perfused for the same total duration as the 
experimental conditions.
An in vivo model of Ang II–induced hypertension (0.8 mg/[kg·d], 
7d) was used to assess the effects of selonsertib (4 mg/[kg·d]) on car-
diac remodeling in male wild-type C57BL/6J (10–12 week) mice. 
In vivo echocardiography was performed using a Vevo2100 system 
(Visualsonics). At the end of the experiment, mouse hearts were ei-
ther perfusion fixed in situ using 10% buffered formalin and embed-
ded for sectioning and histology, or rapidly excised and pulverized in 
liquid nitrogen for biochemical analyses. The use of all animals in our 
studies was performed in accordance with UK Animals (Scientific 
Procedures) Act of 1986 and the European Community Directive 
86/609/EEC for animal experiments.
Statistics
Data are presented as detailed in the figure legends. Data were col-
lected and curated in Microsoft Excel. Statistical analysis used 
GraphPad Prism 8.0 with t tests, 1-way or 2-way ANOVA with Holm-
Sidak multiple comparison post hoc test as indicated. P<0.05 was 
considered statistically significant.
Results
Activation of Cardiac ASK1 Is ROS-Dependent
Our hypothesis is that pathophysiological stresses signal 
through specific MAP3Ks for differential activation of p38-
MAPKs versus JNKs. ASK1 is expressed in all cell types in 
the heart and an established ROS-sensing kinase, whereas 
IL-1β signals through a receptor complex, so these stimuli 
likely use different MAP3Ks. Activation of ASK1 compared 
with an alternative MAP3K (TAK1) was assessed by immu-
noblotting with antibodies to the activation loop phosphoryl-
ation sites. In neonatal rat cardiomyocytes, IL-1β activated 
TAK1, but not ASK1, whereas H2O2 activated ASK1, but not 
TAK1 (Figure 1A). Thus, different stimuli signal through dif-
ferent MAP3Ks. In perfused hearts, H2O2 activated ASK1, 
not TAK1, consistent with the cardiomyocyte response, but 
IL-1β activated both kinases (Figure 1B). We hypothesized 
that IL-1β may activate ASK1 via increased ROS in this con-
text. Indeed, IL-1β significantly increased H2O2 generation in 
perfused hearts (Figure 1C), and perfusion of hearts with the 
ROS/H2O2 scavenger, N-acetyl cysteine, appeared to reduce 
IL-1β–induced ASK1 activation (Figure 1D) suggesting this 
was, indeed, the case. We conclude that ASK1 is selectively 
activated by ROS (which does not activate TAK1), whereas 
IL-1β signals more specifically through TAK1.
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Cardiac ASK1 Signals Selectively to p38-MAPKs, 
not JNKs
ASK1 is reported to promote activation of both p38-MAPKs 
and JNKs.14,15 We used a selective ASK1 inhibitor, selonsertib 
(GS-4997),25 to dissect the signaling pathway in cardiomyo-
cytes (Figure 2) and human cardiac fibroblasts (Figure S1). 
Selonsertib is highly selective for ASK1 (Kd 4.1 nmol/L) with just 2 off-target kinases (DYRK1A, Kd 220 nmol/L; ribosomal 
protein S6 kinase 4, Kd 430 nmol/L) that may be inhibited at 
higher drug concentrations,16 neither of which is expressed at 
significant levels in adult hearts.26 H2O2 (1 mmol/L) activated 
p38-MAPK in rat neonatal cardiomyocytes within 5 minutes, 
whereas activation of JNKs was more pronounced after 15 min-
utes. Pretreatment with selonsertib inhibited activation of p38-
MAPK(s) but not JNKs (Figure 2A). Consistent with the IL-1β 
signal being mediated through an alternative pathway (Figure 
S2), selonsertib did not affect activation of p38-MAPKs or JNKs 
by IL-1β (Figure 2B). In fibroblasts, H2O2 (maximal at 100 
µmol/L; Figure S1A) and IL-1β (maximal at 100 ng/ml; Figure 
S1B) activated p38-MAPKs, but selonsertib only inhibited acti-
vation by H2O2 (Figure S1C). Thus, cardiac ASK1 signals selec-
tively to p38-MAPKs in the context of redox signaling.
The concentration-dependence of ASK1 activation by 
H2O2 in cardiomyocytes was bell-shaped, with activation 
Figure 1. ASK1 (apoptosis signal-regulating kinase 1) is activated by oxidative stress, whereas TAK1 (transforming growth factor–activated kinase 1) is 
activated by IL (interleukin)-1β. A, Rat neonatal cardiomyocytes were exposed to 1 mmol/L H2O2 or 25 ng/mL IL-1β and samples immunoblotted for phospho 
(p) or total ASK1 or TAK1. Left, Representative blots for the acute phase (up to 5 min). Right, Densitometric analysis. Results are means±SEM (n=3). *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 vs vehicle (1-way ANOVA with Holm-Sidak post-test). B, Adult rat hearts were perfused with control (Ctrl), H2O2 (1 mmol/L, 
5 min) or IL-1β (25 ng/mL, 15 min) and samples immunoblotted for phospho (p) or total kinases. Left, Representative immunoblots. Right, Densitometric 
analysis. Results are means±SEM (n=4). **P<0.01, ****P<0.0001 vs controls (one-way ANOVA with Holm-Sidak post-test). C, IL-1β (25 ng/mL, 15 min) 
increased H2O2 generation in adult rat perfused hearts assessed by Amplex Red. Left, Kinetic analysis of catalase-inhibitable fluorescence intensity. Right, 
Quantification of H2O2 production. Results are means±SEM (n=4). *P<0.05 vs vehicle (unpaired t test). D, IL-1β (25 ng/mL, 15 min) induced ASK1 activation is 
reduced by the reactive oxygen species scavenger N-acetyl cysteine (NAC, 4 mmol/L). Results show representative immunoblots from 3 independent samples.
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across a range of concentrations (0.1–10 mmol/L), maximal 
activation at 1 mmol/L (5 minutes), and reduced activation 
at higher concentrations (Figure 3A). H2O2 concentrations 
>1 mmol/L cause cell death,27 but the lack of activation in 
this study (over 5 minutes) is not due to loss of cells be-
cause total ASK1 levels remain the same. Moreover, not all 
kinases become nonresponsive at higher H2O2 concentra-
tions. For example, Akt phosphorylation becomes maximal 
at concentrations >3 mmol/L H2O2 in cardiomyocytes over 
the same duration.28 Thus, the bell-shaped curve for ASK1 
activation (Figure 3A) suggests selective activation only at 
moderate (proapoptotic) concentrations of H2O2. Myocardial 
ischemia is associated with a moderate increase in ROS and 
activation of p38-MAPKs but not JNKs, whereas redox stress 
increases substantially on reperfusion and this leads to acti-
vation of JNKs.9,29 Consistent with this, we detected ASK1 
phosphorylation in perfused rat hearts subjected to ischemia 
and this phosphorylation, together with activation of p38-
MAPKs, was suppressed by the ASK1 inhibitor, selonsertib 
(Figure 3B). In contrast, with ischemia and reperfusion, we 
did not detect phosphorylation of ASK1 (not shown) and 
selonsertib did not inhibit phosphorylation of either p38-
MAPKs or JNKs (Figure 3C). Thus, ASK1 is a redox sensor 
in cardiomyocytes that responds only to moderate changes 
Figure 2. Cardiomyocyte ASK1 (apoptosis signal-regulating kinase 1) selectively signals to p38-MAPK (mitogen-activated protein kinases). Rat neonatal 
cardiomyocytes were exposed to 1 mmol/L H2O2 with/without 1 µM selonsertib (A) or to IL (interleukin)-1β (25 ng/mL, 15 min) with/without 1 or 0.1 µmol/L 
selonsertib (B). Samples were immunoblotted for phospho or total p38-MAPKs or JNKs (c-Jun N-terminal kinases). Selonsertib selectively inhibited 
phosphorylation of p38-MAPKs by H2O2 (A) but not IL-1β (B). Upper, representative immunoblots. Lower, Densitometric analysis. Results are means±SEM 
for n=4 (A) or n=3 (B). *P<0.05, **P<0.01, ***P<0.001 vs vehicle; ###P<0.001 vs H2O2 (1-way ANOVA with Holm-Sidak post-test).
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in ROS levels to mediate ROS-dependent redox signaling to 
p38-MAPKs.
ASK1 Inhibition Reduces Hypertension-Induced 
Cardiac Hypertrophy and Fibrosis
Studies in global knockout mice implicate ASK1 in cardiac 
cell apoptosis in heart failure associated with high myocar-
dial wall stresses (eg, myocardial infarction or pressure-over-
load).20 Knowledge of the role of cardiac ASK1 in models 
associated with more moderate myocardial wall stresses, such 
as hormone-induced hypertension, is limited. We used a 
model of hypertension induced by Ang II in C57Bl/6J male 
mice to assess this. We selected a moderate concentration that 
induces hypertension (0.8 mg/[kg·d] Ang II),30 rather than a 
subpressor dose (eg, 0.288 mg/[kg·d])31 or one more asso-
ciated with sudden cardiac death (eg, >2 mg/[kg·d]). Ang II 
significantly increased mRNA expression of the hypertrophic 
markers Nppa, Nppb, and Myh7. Selonsertib (4 mg/[kg·d]) 
significantly inhibited the increase in expression of Nppa and 
Nppb, but not Myh7 (Figure 4A).
Figure 3. Cardiac ASK1 (apoptosis signal-regulating kinase 1) and p38-MAPKs (mitogen-activated protein kinases) are activated by moderate levels of 
reactive oxygen species. A, Rat neonatal cardiomyocytes were exposed to the indicated concentrations of H2O2 (5 min) and samples immunoblotted for 
phospho or total ASK1. Upper, Representative immunoblots. Lower, Densitometric analysis. Results are means±SEM (n=3). ****P<0.0001 vs vehicle (1-way 
ANOVA with Holm-Sidak post-test). B and C, Adult rat hearts were perfused under control conditions or subjected to ischemia (15 min) alone (B) or with 
reperfusion (I/R; C) with/without 1 µmol/L selonsertib. Samples were immunoblotted for phospho or total ASK1, p38-MAPKs, or JNKs (c-Jun N-terminal 
kinases). Upper, Representative immunoblots. Lower, Densitometric analysis. Individual data points shown with means±SEM (n=4). *P<0.05, **P<0.01, 
****P<0.0001 vs vehicle; ##P<0.01 vs ischemia (2-way ANOVA with Holm-Sidak post-test).
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We used echocardiography to assess cardiac dimensions 
and function at 3 days and then at 7 days (Figure 4B and 
4C). Selonsertib alone did not affect any variables measured 
(Figure S3, Table S2). Ang II increased ejection fraction at 3 
days, and this was not affected by selonsertib. At 3 and 7 days, 
the increase in left ventricular posterior wall thickness (but not 
the decrease in internal diameter) induced by Ang II in both 
systole (Figure 4C) and diastole were inhibited by selonsertib 
suggestive of a selective effect on the structure of the myocar-
dium. Consistent with this, Ang II significantly increased left 
ventricular myocardial cross-sectional area compared with 
vehicle controls, and this was significantly inhibited by sel-
onsertib (Figure 4D). Overall, these results demonstrate that 
ASK1 signaling plays a role in the cardiac hypertrophy result-
ing from hypertension.
Ang II–induced hypertension is associated with increased 
interstitial and perivascular fibrosis,31 increased expression 
of remodeling proteins and enzymes, and elevated levels of 
pathological collagens.32 Cardiac fibrosis was assessed in the 
left ventricular using Masson trichrome (for global collagen 
Figure 4. Selonsertib (Sel) inhibits Ang II (angiotensin II)–induced cardiac hypertrophy. C57Bl/6J mice were treated with 0.8 mg/(kg·d) Ang II with/without 
4 mg/(kg·d) selonsertib for up to 7 d. A, Cardiac RNA was isolated and mRNA expression of hypertrophy-associated genes determined by quantitative 
polymerase chain reaction. Individual data points are shown with means±SEM. *P<0.05, **P<0.01, ***P<0.001 vs vehicle; #P<0.05, ##P<0.01 vs. Ang II (1-way 
ANOVA with Holm-Sidak post-test). B and C, Cardiac function and dimensions were assessed by echocardiography showing representative M-mode images 
of specific mice at baseline and 7 d (B) with quantification of echocardiograms at 3 and 7 d (C). Individual data points shown with means±SEM. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 vs vehicle; ###P<0.001, ####P<0.0001 vs Ang II only (2-way repeated-measures ANOVA with Holm-Sidak post-test). D, 
Selonsertib inhibits Ang II–induced left ventricular (LV) cardiac myocyte hypertrophy assessed by hematoxylin and eosin. Scale bar: 50 µm. Individual data 
points shown with means±SEM. ****P<0.0001 vs vehicle; ###P<0.001 vs Ang II (1-way ANOVA with Holm-Sidak post-test). LVPW indicates LV posterior wall; 
and LVID, LV internal diameter.
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Figure 5. Selonsertib inhibits Ang II (angiotensin II)–induced cardiac fibrosis. C57Bl/6J mice were treated with 0.8 mg/(kg·d) Ang II with/without of 4 mg 
(kg·d) selonsertib for 7 d. A, Heart sections were stained with Trichrome showing fibrosis (blue). Upper, Representative images for left ventricular interstitial 
and perivascular regions. Scale bar: 50 µm. Lower, Quantitative analysis of cardiac fibrosis. Individual data points shown with means±SEM. B, Heart 
sections were stained with picrosirius red for fibrillar collagen. Scale bar: 100 µm. C and D, Cardiac RNA was prepared and mRNA expression of fibrosis and 
remodeling genes (C) or collagens (D) assessed by quantitative polymerase chain reaction. Individual data points shown with means±SEM. E, Heart samples 
were immunoblotted for collagen-1A1 expression. A representative blot is shown (upper) with densitometric analysis for total collagen 1, the cross-linked 
forms (upper bands) or the monomer (lower band) in the lower parts. *P<0.05, **P<0.01, ***P<0.001 vs vehicle; #P<0.05, ##P<0.01 vs Ang II (1-way ANOVA 
with Holm-Sidak post-test).
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deposition; Figure 5A) and picrosirius red (for fibrillar col-
lagens; Figure 5B). Selonsertib significantly reduced cardiac 
fibrosis induced by Ang II, particularly of interstitial rather 
than perivascular fibrosis (Figure 5A, lower). Ang II increased 
mRNA expression of Ddr2 (a fibrosis marker) and Tgfb (that 
drives fibroblast activation), extracellular remodeling-related 
enzymes (Timp1, Lox), a profibrotic signaling molecule 
(Post1), and an extracellular matrix protein (Thbs1). These 
were all reduced in hearts from mice treated with selonsertib, 
although a significant inhibition was only detected for Ddr2 and 
Timp1 (Figure 5C). Ang II increased abundance of the fibrillar 
pathological collagens Col1a1 and Col3a1 and increased the 
basement membrane-linked Col4a1, with no effect on Col2a1 
(Figure 5D). As with other mRNAs assessed, selonsertib par-
tially decreased the response to Ang II. However, selonsertib 
significantly reduced collagen 1 protein expression induced 
by Ang II (Figure 5E). These molecular findings are in accord 
with the reduction in cardiac fibrosis resulting from selon-
sertib treatment of Ang II–induced hypertension detected by 
histology (Figure 5A and 5B).
Ang II–induced hypertension is associated with increased 
myocardial inflammation,33 although whether this precedes 
or is consequential to cardiac fibrosis remains to be defined. 
Ang II increased mRNA expression of proinflammatory cyto-
kines (Figure S4) and inflammatory cell markers (Figure 
S5). Selonsertib did not affect upregulation of inflammatory 
cytokines but significantly reduced expression of myocar-
ditis markers, reflective of protected myocardium. Therefore, 
our data strongly indicate that ASK1 operates as a profibrotic 
signal in the context of hypertension and is a potential thera-
peutic target to reduce pathological cardiac remodeling asso-
ciated with this (Figure 6).
Discussion
In recent years, ASK1 has emerged as a therapeutic target for 
fibrotic diseases, with ASK1 inhibitors in phase-III clinical 
trials for chronic kidney disease and nonalcoholic steatohepa-
titis.16,17 Here, we show that ASK1 inhibitors, such as selon-
sertib, have potential therapeutic value in hypertensive heart 
disease, reducing cardiac fibrosis together with cardiomyo-
cyte hypertrophy (Figure 6). Thus, targeting the ASK1→p38-
MAPK nexus has potential therapeutic viability as a treatment 
for hypertensive heart disease.
Our data with selonsertib are consistent with previous stud-
ies of mice with global ASK1 deletion subjected to a low dose 
of Ang II (0.288 mg/[kg·d]) in which cardiac hypertrophy and 
fibrosis were reduced.31 Our study used a higher hypertensive 
concentration of Ang II (0.8 mg/[kg·d]),30 resulting in greater 
fibrosis and hypertrophy and, still, selonsertib was effective at 
reducing both (Figures 4 and 5). Several studies indicate that 
ASK1 (as its name suggests) promotes cardiomyocyte death. 
Thus, global ASK1 knockout mice subjected to myocardial in-
farction or pressure-overload (models with much higher wall 
stresses than with Ang II–induced hypertension that is partic-
ularly associated with cardiomyocyte death) exhibit reduced 
cardiac hypertrophy and remodeling.20 Furthermore, cardio-
myocyte overexpression of ASK1 increases cardiomyocyte 
apoptosis in response to stressors, exacerbating progression 
to heart failure in myocardial infarction and pressure-overload 
mouse models.14 ASK1 overexpression in cardiomyocytes does 
not promote hypertrophy in vivo per se,14 yet selonsertib in-
hibited cardiomyocyte hypertrophy in Ang II–induced hyper-
tension (Figure 4). Here, it is important to consider the in vivo 
context taking into account the established profibrotic effects 
of ASK1. ASK1 inhibitors do not appear to affect blood pres-
sure in humans (Selonsertib in adults with pulmonary arterial 
hypertension and Safety and Efficacy of Selonsertib in Adults 
With Nonalcoholic Steatohapetitis [NASH] and Bridging [F3] 
Fibrosis trials16,17,34,35) or in a mouse model of kidney fibrosis 
associated with hypertension,36 so it is unlikely that the reduc-
tion in cardiac fibrosis and cardiomyocyte hypertrophy with 
selonsertib seen in our studies with Ang II are due to an effect 
on blood pressure. It is more that the inhibition of fibrosis by 
selonsertib, associated with reduced paracrine signaling and 
inflammation, reduces cardiomyocyte workload, improving 
cardiomyocyte survival. The lower overall workload means 
that cardiomyocyte hypertrophy is also reduced.
As a ROS-sensing kinase, ASK1 is sensitive to an array 
of physiological and pathological processes and stimuli. Our 
data clearly support this because ASK1 is activated in cells in 
a time- and dose-dependent manner by direct redox challenge 
with H2O2 (Figures 1 and 2). However, ASK1 was activated 
by moderate levels of ROS (Figure 3) classically associated 
with apoptosis.27 In contrast, high levels of oxidative stress 
more associated with necrotic forms of cell death did not ac-
tivate ASK1 which has a bell-shaped dose-response curve. In 
accord with this, ASK1 was activated only by ischemia (as-
sociated with moderate levels of ROS) in perfused hearts, but 
not on reperfusion (with much higher levels of ROS).29 Our 
data for ASK1 are consistent with previous studies of myocar-
dial infarction in ASK1 knockout mice.20 Here, ASK1 deletion 
reduced the percentage of apoptotic cardiomyocytes particu-
larly in the peri-infarct zone, a region likely to be subjected to 
lower ROS levels than cells in the infarct zone itself. It is dif-
ficult to correlate the levels of exogenously applied H2O2 with 
endogenous levels. However, IL-1β treated hearts exhibited 
an increase of ≈60 µmol/L H2O2 per mg of protein in perfused 
rat hearts (Figure 1C), so allowing for degradation of exoge-
nous H2O2 as it enters cells, together with loss of endogenous 
H2O2 on production from the heart, the concentrations of H2O2 
required to activate ASK1 (Figures 1 and 2) are in an appro-
priate range.
Other stimuli, although not activating ASK1 directly, may 
still activate ASK1 via secondary production of ROS. This 
appears to be the case with IL-1β which activated ASK1 in 
an intact perfused heart in which it increased oxidative stress 
(Figure 1). We could not detect activation of ASK1 in car-
diomyocytes at any concentration of IL-1β that we studied 
(Figure S2). The reason is not clear, but the environment of 
cultured cardiomyocytes which have a good nutrient supply 
and efficient gas exchange contrasts with that of an intact beat-
ing heart in an ex vivo perfusion setting. The latter is under 
greater stress and subject to greater constraints with respect to 
oxygen supply and demand. This may deplete antioxidant re-
serves more rapidly and any small effect of IL-1β to increase 
ROS may be exaggerated to a sufficient degree that ASK1 
may be activated. Other proinflammatory cytokines also acti-
vate ROS and stimulate ASK1 indirectly. For example, TNFα 
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(tumor necrosis factor-α) signals through the ROS-generating 
NADPH oxidase, NADPH oxidase-1, to activate ASK1 in vas-
cular smooth muscle cells.37 Proinflammatory cytokines alone 
do not promote apoptosis in primary neonatal cardiomyo-
cytes,38 but the question remains of whether proinflammatory 
cytokines promote apoptosis via a ROS-ASK1 sensing system 
in compromised cells. The rheostat-like response of ASK1 to 
redox stress is in accord with our previous work showing that 
different degrees of oxidative stress differentially regulate sig-
naling pathways and gene/protein expression.24 For ASK1, ac-
tivation by moderate levels of ROS is likely to favor regulated 
(less damaging) forms of cell death such as apoptosis over 
unregulated necrotic cell death associated with a high level of 
inflammation.
ASK1 is implicated in activation of p38-MAPKs or JNKs 
in a plethora of studies in many different cells,39 raising a 
question of signal specificity. In cardiomyocytes and the heart 
overall, our data demonstrated that the signal from ASK1 is 
highly specific for p38-MAPK activation with little/no input 
into JNKs (Figures 2 and 3). In contrast, TAK1, as activated by 
IL-1β, activates both MAPK pathways (Figure 2; Figure S2), 
with cross-talk to ASK1 only in the intact heart consequential 
to an altered redox balance. One factor may be the hard-wiring 
of signaling networks in primary cells, particularly terminally 
differentiated cells, such as cardiomyocytes. However, al-
though our data are consistent with previous studies in per-
fused hearts showing that ASK1 is activated in concert with 
p38-MAPKs,15 they contrast with other studies of the heart 
suggesting that ASK1 activates JNKs.14,40 It should be borne 
in mind that JNKs and p38-MAPKs are both stress-responsive, 
and interfering with one pathway via genetic modification may 
result in an increased stress that influences the other, making 
it difficult to dissect the signaling. For example, although car-
diomyocyte ASK1 overexpression is associated with increased 
activation of JNKs (rather than p38-MAPKs) with pressure-
overload over 1 to 8 weeks,14 this may be secondary to the 
remodeling response which includes enhanced fibrosis and in-
flammation. In our case, by using a small molecule inhibitor, 
we were able to assess the acute (ie, direct) signaling pathway.
Although there is much speculation and suggestion that 
ASK1 inhibitors may be useful for cardiac diseases,16,17,21 
such drugs are not yet being assessed in clinical trials for this 
purpose. They have been tested in relation to nonalcoholic 
steatohepatitis, chronic kidney disease, and pulmonary hy-
pertension in phase-II or phase-III trials,16 so they are clearly 
considered safe. Our data with selonsertib support the concept 
that reducing ASK1 activity in the heart is a desirable strategy 
for reducing fibrosis and thus the workload of the heart in 
disease states such as hypertension and is independent of a 
direct effect on blood pressure.36 Other studies with geneti-
cally modified mice indicate that ASK1 is also a strong ther-
apeutic target in myocardial infarction in which inhibition of 
ASK1 may facilitate cardiomyocyte survival. A caveat is that 
because ASK1 is involved in fibrosis, inhibiting ASK1 may 
Figure 6. Schematic representation of 
ASK1 (apoptosis signal-regulating kinase 1) 
signaling in the heart. Cardiac cell stresses, 
such as ischemia and Ang II (angiotensin II), 
along with IL (interleukin)-1β to some extent, 
increase reactive oxygen species (ROS) 
signaling in the heart. These stressors or direct 
application of H2O2 lead to ASK1 activation. 
In contrast, redox signaling does not activate 
TAK1 (transforming growth factor–activated 
kinase 1), which is activated directly by 
IL-1β. In cardiomyocytes, ASK1 signals 
selectively to p38-MAPKs (mitogen-activated 
protein kinases), which, in the context of Ang 
II–induced hypertension in vivo, results in 
cardiac fibrosis and inflammation. This, in turn, 
increases cardiomyocyte workload, resulting in 
cardiomyocyte hypertrophy. Continued stress 
leads to cardiomyocyte apoptosis exacerbating 
cardiac fibrosis/inflammation. This destructive 
cycle of cardiac remodeling is broken by 
selonsertib, a selective ASK1 inhibitor. MKK 
indicates MAPK kinase.
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have a detrimental effect on establishing a stable fibrotic scar. 
It may be important, therefore, to tailor the therapy towards 
hypertension-associated cardiac dysfunction or other cardiac 
diseases with pronounced interstitial fibrosis.
Perspective
Hypertensive heart disease is a poorly controlled and progres-
sive condition associated with myocardial fibrosis, along with 
cardiomyocyte dysfunction and death, cumulating in cardiac 
stiffening and heart failure. This study demonstrates that the 
ROS-sensing enzyme ASK1 represents an ideal therapeutic 
target for hypertensive heart disease. ASK1 inhibitors are de-
veloped as antifibrotic therapies in other diseases and may be 
useful for hypertensive heart disease, reducing fibrosis and, 
therefore, improving cardiac function. At a mechanistic level, 
our data define a very specific ROS→ASK1→p38-MAPK 
signaling modality, suggesting that p38-MAPK(s) play a sig-
nificant role in development of cardiac fibrosis. Clearly, other 
components of the pathway constitute alternative therapeutic 
targets. Thus, targeting the ASK1→p38-MAPK nexus in the 
heart has potential therapeutic viability as a treatment for hy-
pertensive heart disease.
Sources of Funding
This work was supported by the British Heart Foundation (grant 
numbers PG/13/71/30460, PG/17/11/32841, PG/15/24/31367, 
PG/15/31/31393, FS/18/33/33621, FS/19/24/34262) and the 
Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z).
Acknowledgments
D.N. Meijles and A. Clerk conceived and designed the experiments. 
D.N. Meijles, J.J. Cull, T. Markou, S.T.E. Cooper, Z.H.R. Haines, 
S.J. Fuller, P. O’Gara, and A. Clerk performed the experiments. D.N. 
Meijles, T. Markou, M.N. Sheppard, S.E. Harding, P.H. Sugden, 
and A. Clerk analyzed and interpreted the data. D.N. Meijles, P.H. 
Sugden, and A.Clerk drafted and edited the article.
Disclosures
None.
References
 1. Savarese G, Lund LH. Global public health burden of heart failure. Card 
Fail Rev. 2017;3:7–11. doi: 10.15420/cfr.2016:25:2
 2. Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hyper-
trophy: eschew obfuscation. Circ Res. 2003;92:1171–1175. doi: 
10.1161/01.RES.0000077012.11088.BC
 3. Zhang J, Liu D, Zhang M, Zhang Y. Programmed necrosis in cardio-
myocytes: mitochondria, death receptors and beyond. Br J Pharmacol. 
2019;176:4319–4339. doi: 10.1111/bph.14363
 4. Teo LY, Chan LL, Lam CS. Heart failure with preserved ejection frac-
tion in hypertension. Curr Opin Cardiol. 2016;31:410–416. doi: 
10.1097/HCO.0000000000000292
 5. Suthahar N, Meijers WC, Silljé HHW, de Boer RA. From inflammation to 
fibrosis-molecular and cellular mechanisms of myocardial tissue remodel-
ling and perspectives on differential treatment opportunities. Curr Heart 
Fail Rep. 2017;14:235–250. doi: 10.1007/s11897-017-0343-y
 6. Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, 
Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knöll R, et al. Targeting myo-
cardial remodelling to develop novel therapies for heart failure: a position 
paper from the working group on myocardial function of the European 
society of cardiology. Eur J Heart Fail. 2014;16:494–508. doi: 
10.1002/ejhf.62
 7. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling 
in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 
2010;90:1507–1546. doi: 10.1152/physrev.00054.2009
 8. Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of “stress-regu-
lated” mitogen-activated protein kinases (stress-activated protein kinases/
c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) 
in perfused rat hearts by oxidative and other stresses. J Biol Chem. 
1998;273:7228–7234. doi: 10.1074/jbc.273.13.7228
 9. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, 
Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH. Stimulation of the 
stress-activated mitogen-activated protein kinase subfamilies in perfused 
heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal 
kinases are activated by ischemia/reperfusion. Circ Res. 1996;79:162–
173. doi: 10.1161/01.res.79.2.162
 10. Meijles DN, Pagano PJ. Nox and inflammation in the vascular adventitia. 
 Hypertension. 2016;67:14–19. doi: 10.1161/HYPERTENSIONAHA. 
115.03622
 11. Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target 
for heart failure therapy? J Am Coll Cardiol. 2006;48:556–558. doi: 
10.1016/j.jacc.2006.05.005
 12. Winter-Vann AM, Johnson GL. Integrated activation of MAP3Ks bal-
ances cell fate in response to stress. J Cell Biochem. 2007;102:848–858. 
doi: 10.1002/jcb.21522
 13. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, 
Michael LH, Overbeek PA, Schneider MD. TAK1 is activated in the my-
ocardium after pressure overload and is sufficient to provoke heart failure 
in transgenic mice. Nat Med. 2000;6:556–563. doi: 10.1038/75037
 14. Liu Q, Sargent MA, York AJ, Molkentin JD. ASK1 regulates car-
diomyocyte death but not hypertrophy in transgenic mice. Circ Res. 
2009;105:1110–1117. doi: 10.1161/CIRCRESAHA.109.200741
 15. Harding SJ, Browne GJ, Miller BW, Prigent SA, Dickens M. 
Activation of ASK1, downstream MAPKK and MAPK isoforms dur-
ing cardiac ischaemia. Biochim Biophys Acta. 2010;1802:733–740. doi: 
10.1016/j.bbadis.2010.06.005
 16. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, 
Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, et al; GS-US-
384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with 
nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 
2018;67:549–559. doi: 10.1002/hep.29514
 17. Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-
US-223-1015 Investigators. Effects of selonsertib in patients with di-
abetic kidney disease. J Am Soc Nephrol. 2019;30:1980–1990. doi: 
10.1681/ASN.2018121231
 18. Toldo S, Breckenridge DG, Mezzaroma E, Van Tassell BW, Shryock J, 
Kannan H, Phan D, Budas G, Farkas D, Lesnefsky E, et al. Inhibition 
of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-
reperfusion injury in the mouse. J Am Heart Assoc. 2012;1:e002360. doi: 
10.1161/JAHA.112.002360
 19. Nako H, Kataoka K, Koibuchi N, Dong YF, Toyama K, Yamamoto E, 
Yasuda O, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism 
of angiotensin II-induced cardiac injury in hypertensive rats: the crit-
ical role of ASK1 and VEGF. Hypertens Res. 2012;35:194–200. doi: 
10.1038/hr.2011.175
 20. Yamaguchi O, Higuchi Y, Hirotani S, Kashiwase K, Nakayama H, 
Hikoso S, Takeda T, Watanabe T, Asahi M, Taniike M, et al. Targeted de-
letion of apoptosis signal-regulating kinase 1 attenuates left ventricular 
remodeling. Proc Natl Acad Sci U S A. 2003;100:15883–15888. doi: 
10.1073/pnas.2136717100
 21. Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, 
Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, 
et al. ASK1 inhibition halts disease progression in preclinical mod-
els of pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2018;197:373–385. doi: 10.1164/rccm.201703-0502OC
 22. Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, 
Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, et al. Structure-
based design of ASK1 inhibitors as potential agents for heart failure. ACS 
Med Chem Lett. 2017;8:316–320. doi: 10.1021/acsmedchemlett.6b00481
 23. Marshall AK, Barrett OP, Cullingford TE, Shanmugasundram A, 
Sugden PH, Clerk A. ERK1/2 signaling dominates over RhoA signal-
ing in regulating early changes in RNA expression induced by endothe-
lin-1 in neonatal rat cardiomyocytes. PLoS One. 2010;5:e10027. doi: 
10.1371/journal.pone.0010027
 24. Meijles DN, Zoumpoulidou G, Markou T, Rostron KA, Patel R, Lay K, 
Handa BS, Wong B, Sugden PH, Clerk A. The cardiomyocyte “redox rhe-
ostat”: redox signalling via the AMPK-mTOR axis and regulation of gene 
and protein expression balancing survival and death. J Mol Cell Cardiol. 
2019;129:118–129. doi: 10.1016/j.yjmcc.2019.02.006
D
ow
nloaded from
 http://ahajournals.org by on September 25, 2020
1218  Hypertension  October 2020
 25. Lin JH, Zhang JJ, Lin SL, Chertow GM. Design of a phase 2 clinical trial 
of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. 
Nephron. 2015;129:29–33. doi: 10.1159/000369152
 26. Fuller SJ, Osborne SA, Leonard SJ, Hardyman MA, Vaniotis G, Allen BG, 
Sugden PH, Clerk A. Cardiac protein kinases: the cardiomyocyte kinome 
and differential kinase expression in human failing hearts. Cardiovasc 
Res. 2015;108:87–98. doi: 10.1093/cvr/cvv210
 27. Cook SA, Sugden PH, Clerk A. Regulation of bcl-2 family proteins dur-
ing development and in response to oxidative stress in cardiac myocytes: 
association with changes in mitochondrial membrane potential. Circ Res. 
1999;85:940–949. doi: 10.1161/01.res.85.10.940
 28. Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 
4E-BP1 by oxidative stress in cardiac myocytes. Circ Res. 2000;86:1252–
1258. doi: 10.1161/01.res.86.12.1252
 29. Becker LB. New concepts in reactive oxygen species and cardiovas-
cular reperfusion physiology. Cardiovasc Res. 2004;61:461–470. doi: 
10.1016/j.cardiores.2003.10.025
 30. Patel J, Douglas G, Kerr AG, Hale AB, Channon KM. Effect of irradi-
ation and bone marrow transplantation on angiotensin II-induced aortic 
inflammation in ApoE knockout mice. Atherosclerosis. 2018;276:74–82. 
doi: 10.1016/j.atherosclerosis.2018.07.019
 31. Izumiya Y, Kim S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, 
Ichijo H, Iwao H. Apoptosis signal-regulating kinase 1 plays a pivotal role 
in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res. 
2003;93:874–883. doi: 10.1161/01.RES.0000100665.67510.F5
 32. Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv 
Cardiovasc Dis. 2016;10:162–171. doi: 10.1177/1753944716642677
 33. Ma F, Feng J, Zhang C, Li Y, Qi G, Li H, Wu Y, Fu Y, Zhao Y, Chen H, 
et al. The requirement of CD8+ T cells to initiate and augment acute 
cardiac inflammatory response to high blood pressure. J Immunol. 
2014;192:3365–3373. doi: 10.4049/jimmunol.1301522
 34. Nelson CH, Etchevers K, Yi S, Breckenridge D, Hepner M, Patel U, 
Ling J, Mathias A. Pharmacokinetics, safety, and tolerability of selon-
sertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, following 
first-in-human single and multiple ascending doses in healthy subjects. 
Clin Pharmacokinet. 2020. doi:10.1007/s40262-020-00878-y 
 35. Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, 
Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, et al; STELLAR-3 
and STELLAR-4 Investigators. Selonsertib for patients with bridg-
ing fibrosis or compensated cirrhosis due to NASH: Results from ran-
domized phase III STELLAR trials. J Hepatol. 2020;73:26–39. doi: 
10.1016/j.jhep.2020.02.027
 36. Liles JT, Corkey BK, Notte GT, Budas GR, Lansdon EB, 
Hinojosa-Kirschenbaum F, Badal SS, Lee M, Schultz BE, Wise S, et al. 
ASK1 contributes to fibrosis and dysfunction in models of kidney disease. 
J Clin Invest. 2018;128:4485–4500. doi: 10.1172/JCI99768
 37. Choi H, Stark RJ, Raja BS, Dikalova A, Lamb FS. Apoptosis signal-regu-
lating kinase 1 activation by Nox1-derived oxidants is required for TNFα 
receptor endocytosis. Am J Physiol Heart Circ Physiol. 2019;316:H1528–
H1537. doi: 10.1152/ajpheart.00741.2018
 38. Cook SA, Poole-Wilson PA. Cardiac myocyte apoptosis. Eur Heart J. 
1999;20:1619–1629. doi: 10.1053/euhj.1999.1548
 39. Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family pro-
teins in stress responses and diseases. Cell Commun Signal. 2009;7:9. doi: 
10.1186/1478-811X-7-9
 40. Wu QQ, Xu M, Yuan Y, Li FF, Yang Z, Liu Y, Zhou MQ, Bian ZY, Deng W, 
Gao L, et al. Cathepsin B deficiency attenuates cardiac remodeling in response 
to pressure overload via TNF-α/ASK1/JNK pathway. Am J Physiol Heart 
Circ Physiol. 2015;308:H1143–H1154. doi: 10.1152/ajpheart.00601.2014
What Is New?
•	We established that reactive oxygen species signals through ASK1 
(apoptosis signal-regulating kinase 1) exclusively to p38-MAPK (mito-
gen-activated protein kinases) in the heart, accounting for activation 
of p38-MAPK in ischemia. Inhibiting ASK1 reduced cardiac fibrosis in 
hypertension-induced cardiac hypertrophy in mice in vivo.
What Is Relevant?
•	Because cardiac fibrosis predisposes to heart failure, ASK1 inhibitors (in 
clinical trials for other fibrosis-associated diseases) may be therapeuti-
cally useful for hypertension-associated cardiac hypertrophy, reducing or 
preventing progression to heart failure in humans.
Summary
Our data establish that a reactive oxygen species-ASK1-p38-MAPK 
signal operates in the heart and, in the context of hypertension, this 
is linked to increased cardiac fibrosis. Targeting ASK1 with existing 
small molecule inhibitors may be beneficial in hypertensive heart 
disease, reducing cardiac fibrosis and, thus, maintaining cardiac 
function.
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